ASPIRE: Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease

Sponsor

Cardium Therapeutics (Industry)

Overall Status

Terminated

CT.gov ID

NCT01550614

Collaborator

Advanced Biosciences Research (Other)

Enrollment

Location

Arms

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4, delivered during induced transient ischemia, is effective in improving myocardial perfusion, angina functional class, patient symptoms, and quality of life. Short-term (8 weeks) and long-term (12 month) safety of Ad5FGF-4 will also be evaluated. The primary endpoint is change in adenosine triphosphate (ATP) stress SPECT reperfusion defect size.

Condition or Disease	Intervention/Treatment	Phase
Angina, Stable	Genetic: Alferminogene tadenovec	Phase 3

Study Design

Study Type:

Interventional

Actual Enrollment :

11 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomized, Controlled, Parallel Group, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging in Patients With Stable Angina Pectoris

Study Start Date :

Mar 1, 2012

Actual Primary Completion Date :

May 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A: Ad5FGF-4 Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication	Genetic: Alferminogene tadenovec One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer) Other Names: Generx Cardionovo (Russian Trade Name)
No Intervention: Arm B Standard of care angina medication

Arm

Intervention/Treatment

Experimental: Arm A: Ad5FGF-4

Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication

Genetic: Alferminogene tadenovec

One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)

Other Names:

Generx

Cardionovo (Russian Trade Name)

No Intervention: Arm B

Standard of care angina medication

Outcome Measures

Primary Outcome Measures

Change in reversible perfusion defect size (RPDS) as measured by adenosine triphosphate (ATP) single-photon emission computed tomography with technetium-99m sestamibi (SPECT) [Baseline and Week 8]

Secondary Outcome Measures

Change in angina frequency and nitroglycerin use [Baseline and Week 8]
Change in quality of life using the Seattle Angina Questionnaire [Baseline and Week 8]
Change in patient functional class using CCS anginal classification [Baseline and Week 8]
Safety of Ad5FGF-4 as assessed by adverse events and clinical laboratory testing [Through Week 8]
Long-term safety of Ad5FGF-4 as assessed by serious adverse events [Through Month 12]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients 18-75 years of age, inclusive
Postmenopausal female patients, women of childbearing potential and men willing to use an effective contraception method while on the study treatment and/or who agree not to become pregnant or make their partner pregnant throughout the study and during one year after administration of the study drug
Female subjects of childbearing potential who have a negative urine pregnancy test, and are willing to use an acceptable form of birth control during the study
Diagnostic coronary angiogram in the past confirming the presence of coronary artery disease. Patients with extensive disease, or high risk for intervention, or who don't want the higher risk angioplasty or surgery, or have had angioplasty with recurrent angina and vessels are not ideal for angioplasty are ideal candidates
Stable angina pectoris being treated with chronic anti-anginal medication(s) at a stable dose for 2 weeks prior to randomization
Left ventricular ejection fraction (LVEF) of ≥30%. If the LVEF is <30% the patient can be enrolled if there is no recent or current congestive heart failure present
Evidence of stress induced myocardial ischemia by ATP technetium-99m sestamibi SPECT, defined as a reversible perfusion defect size of ≥9%
Willing and able to comply with the study requirements
Provided written informed consent

Exclusion Criteria:

Female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study and one year after administration of the study drug. Women of child bearing potential who are not using an acceptable method of birth control. Women of child bearing potential with a positive urine pregnancy test within 24 hours prior to the start of investigational product
Patients with unstable angina for whom an immediate revascularization procedure is indicated
Patients for whom a cardiac revascularization procedure is planned in the next 3 months
Myocardial infarction within the 3 months prior to the Screening visit
Congestive heart failure NYHA Class IV
Myocarditis or restrictive pericarditis
Left main coronary stenosis ≥70% (unless the patient has a patent graft or collateral vessels supplying the left coronary circulation) or proximal stenoses ≥70% in all major coronary conduit vessels (coronary arteries and bypass grafts)
A single patent coronary conduit (for example, totally occluded RCA and LCx with no bypass grafts. Patient will not tolerate balloon occlusion of the LAD for infusion)
Clinically significant aortic or mitral valvular heart disease.
Life threatening coronary ostial stenosis that precludes adequate catheter engagement in any target vessel, unless the vessel can be accessed via a patent bypass graft
Coronary artery to venous communications, which bypass the coronary capillary bed
Untreated life-threatening ventricular arrhythmias
Uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic pressure >100 mm Hg
CABG surgery within the past 6 months, unless those grafts are now occluded
Percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months, unless the stented/dilated vessel(s) are now occluded
Enhanced external counterpulsation (EECP) within 3 months prior to the start of screening evaluations
Transmyocardial or percutaneous myocardial laser revascularization within the previous year
Prior treatment with any cardiovascular gene therapy
Patients who received an investigational drug or biologic within 30 days of screening or are currently participating in an investigational drug, biologic or device trial